Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.7 - $1.56 $16,823 - $37,491
-24,033 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$1.37 - $2.43 $3,915 - $6,944
-2,858 Reduced 10.63%
24,033 $33,000
Q4 2021

Feb 11, 2022

BUY
$2.27 - $4.39 $3,248 - $6,282
1,431 Added 5.62%
26,891 $61,000
Q3 2021

Nov 04, 2021

SELL
$3.37 - $4.76 $137,897 - $194,774
-40,919 Reduced 61.64%
25,460 $106,000
Q2 2021

Aug 11, 2021

BUY
$4.75 - $9.39 $315,300 - $623,298
66,379 New
66,379 $315,000
Q4 2019

Feb 14, 2020

SELL
$3.75 - $6.11 $15 - $24
-4 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$3.87 - $6.13 $35,847 - $56,782
-9,263 Reduced 99.96%
4 $0
Q2 2019

Aug 14, 2019

BUY
$4.86 - $9.24 $45,037 - $85,627
9,267 New
9,267 $60,000

Others Institutions Holding ONCT

About Oncternal Therapeutics, Inc.


  • Ticker ONCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,517,200
  • Market Cap $29.4M
  • Description
  • Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...
More about ONCT
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.